Proteomics, Genomics & Microarrays
Precision medicine in practice: The future of AD diagnostics and treatment
The precision medicine approach in AD envisions stratifying patients by genetic, proteomic and metabolic markers to tailor interventions. The endgame of these efforts is a seamless translation of molecular data into actionable clinical insights. A world in which a patient’s biomarker profi le - built on genomics, transcriptomics, proteomics and metabolomics - is used to defi ne the right treatment, at the right time, in the right sequence, for the right patient. For all patients, whether it’s diagnosing preclinical AD, forecasting cognitive decline, or personalising drug regimens, the future lies in composite biomarker panels and integrated precision platforms. Danaher’s ecosystem
References
1. World Health Organization. Dementia. Key facts. March 31, 2025. Available at:
https://www.who.int/news-room/fact-sheets/detail/dementia (accessed May 21, 2025).
2. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125. doi: 10.1016/S2468-2667(21)00249-8. Epub 2022 Jan 6.
3. Erichsen J, Craft S. Targeting immunometabolic pathways for combination therapy in Alzheimer’s disease. Alzheimers Dement (N Y). 2023;9(4):e12423. doi: 10.1002/trc2.12423.
4. de la Monte SM, Wands JR. Alzheimer’s Disease Is Type 3 Diabetes–Evidence Reviewed. J Diabetes Sci Technol. 2008;2(6):1101–1113. doi: 10.1177/193229680800200619.
5. de la Monte SM. Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today? J Alzheimers Dis. 2024;101(Suppl 1):S317–S343. doi: 10.3233/JAD-24006.
6. Barbera M, et al. A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol. Alzheimers Res Ther. 2024 Jan 31;16:23. doi: 10.1186/s13195-023-01355-x.
7. Cao F, et al. The relationship between diabetes and the dementia risk: a meta-analysis. Diabetol Metab Syndr. 2024;16(1):101. doi: 10.1186/s13098-024-01346-4.
8. Beckman Coulter. Empowering Neurodegenerative Disease Research. Blood-based Neurology Disease Assays. Available at:
https://www.beckmancoulter.com/products/immunoassay/ neurology#assay (accessed May 21, 2025).
9. Thijssen EH, et al. Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer’s disease. Alzheimer’s Dement. 2020;16(Suppl. 5):e038179. doi: 10.1002/alz.038179.
10. Beckman Coulter. Information Bulletin. Using the new Access p-Tau217 (RUO) assay in your laboratory. Available at:
https://media.beckmancoulter. com/-/media/diagnostics/products/immunoassay/neurology/docs/d26743-aa. pdf?rev=d7873e5aea574241bf0ff0f8d7eea64e&hash=CEB4F073C9514336B06B115477B7F2C2 (accessed May 21, 2025).
11. Beckman Coulter. Information Bulletin. Using the new Access APOE Ɛ4 (RUO) assay in your laboratory. Available at:
https://media.beckmancoulter.com/-/media/ diagnostics/products/immunoassay/neurology/docs/apoe-ruo-information-bulletin. pdf?rev=924744a7d8d343ccb4cb68953dda8166&hash=8BE199FF1EFF96711D4F629B3A6D9B1D (accessed May 21, 2025).
12. Beckman Coulter. Information Bulletin. Using the new Access NfL (RUO) assay in your laboratory. Available at:
https://media.beckmancoulter.com/-/media/ diagnostics/products/immunoassay/neurology/docs/nfl -ruo-information-bulletin. pdf?rev=18523f86bc8e40829dad8c7297df5864&hash=68A8B1BBC4B4EEFB765FAA14959561B8 (accessed May 21, 2025).
13. Beckman Coulter. Information Bulletin. Using the new Access GFAP (RUO) assay in your laboratory. Available at:
https://media.beckmancoulter.com/-/media/ diagnostics/products/immunoassay/neurology/docs/gfap-ruo-information-bulletin. pdf?rev=0731576d58e84ce08a62ab330cd3f97d&hash=FCD35A5E8498A78AC209A490F2D70833 (accessed May 21, 2025).
14. US Food and Drug Administration. FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease. FDA News Release. May 16, 2025. Available at:
https://www.fda.gov/news-events/press- announcements/fda-clears-fi rst-blood-test-used-diagnosing-alzheimers-disease (accessed May 21, 2025).
15. Biogen. Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease. Release Details. July 30, 2024. Available at: https://
investors.biogen.com/news-releases/news-release-details/biogen-beckman-coulter-and-fujirebio- collaborate-blood-based (accessed May 21, 2025).
16. Beckman Coulter. Beckman Coulter Receives FDA Breakthrough Device Designation for Alzheimer’s Disease Blood Test. Press release. January 28, 2025. Available at: https://news.
beckmancoulter.com/2025-01-28-Beckman-Coulter-Receives-FDA-Breakthrough-Device-Designation- for-Alzheimers-Disease-Blood-Test (accessed May 21, 2025).
17. Biogen. Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease. Press release. July 30, 2024. Available at: https://
investors.biogen.com/node/28221/pdf (accessed May 21, 2025).
18. Leonenko G, et al. Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores. Nat Commun. 2021 Jul 23;12(1):4506. doi: 10.1038/s41467-021-24082-z.
19. Castrillo JI, et al. Systems Biology Methods for Alzheimer’s Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. Methods Mol Biol. 2018:1750:31-66. doi: 10.1007/978-1-4939-7704-8_3.
20. Danaher. Danaher, Innovative Genomics Institute join forces. News Article. January 9, 2024. Available at:
https://danaher.com/landmark-partnership-crispr-drug-development (accessed May 21, 2025).
21. Danaher. Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution. January 9, 2024. Available at:
https://lifesciences.danaher.com/us/en/news/danaher-igi-
beacon-for-crispr-cures.html (accessed May 21, 2025).
22. Aldevron and Integrated DNA Technologies Manufacture World’s First mRNA-based Personalized CRISPR Therapy. CRISPR Medicine News. May. 15, 2025. Available at: https://crisprmedicinenews. com/press-release-service/card/aldevron-and-integrated-dna-technologies-manufacture-worlds- fi rst-mrna-based-personalized-crispr-th/ (accessed May 21, 2025).
23. Macha K, et al. Functional characterization of healthy Alzheimer’s disease-related 3D neurospheres formed using human iPSC-derived glutamatergic neurons, GABAergic neurons, and astrocytes. Molecular Devices, and FUJIFILM Cellular Dynamics, Inc. Scientifi c Poster. 2024. Available at:
https://www.moleculardevices.com/en/assets/scientifi c-posters/dd/fl ipr/functional- characterization-of-alzheimers-disease-related-3d-neurospheres-using-human-ipsc-derived- glutamatergic (accessed May 21, 2025).
24. Rudolf R. Notable AI-based Solutions for Phenotypic Drug Screening. Leica Microsystems. Webinar. December 6, 2023. Available at:
https://www.leica-microsystems.com/science-lab/life- science/notable-ai-based-solutions-for-phenotypic-drug-screening/ (accessed May 21, 2025).
25. Zaltsman A, Bashkurov M, Hwang Y-C. Label-free cell segmentation with IN Carta SINAP application module. Molecular Devices. Application Note. Available at: https://www.
moleculardevices.com/en/assets/app-note/dd/img/label-free-cell-segmentation-with-in-carta-sinap- application-module (accessed May 21, 2025).
26. Sirenko O, Fedorov D, Goldberg I. AI-based analysis of complex biological phenotypes. Molecular Devices, and ViQi, Inc. Scientifi c Poster. 2020. Available at:
https://www.moleculardevices.com/ sites/default/fi les/en/assets/scientifi c-posters/dd/img/ai-based-analysis-of-complex-biological- phenotypes.pdf (accessed May 21, 2025).
27. Salinas C. Artifi cial Intelligence in Pathology: Challenges and Considerations. Leica Biosystems. Educational Article. Available at:
https://www.leicabiosystems.com/educational-resources/articles/ artifi cial-intelligence-pathology-challenges-and-considerations/ (accessed May 21, 2025).
28. Dayal S, Heath J. Biomarkers. Leica Biosystems. Educational Article. Available at: https://www.
leicabiosystems.com/educational-resources/articles/biomarkers/ (accessed May 21, 2025).
29. Leica Biosystems, and Indica Labs. Leica Biosystems and Indica Labs Announce Signifi cant Strategic Investment and Creation of Digital Pathology Platform. Leica Biosystems. Press release. January 8, 2025.Available at:
https://www.leicabiosystems.com/news-events/leica- biosystems-and-indica-labs-announce-signifi cant-strategic-investment-and-creation/ (accessed May 21, 2025).
30. Indica Labs. Indica Labs Announces AI-Powered HALO® Software Release for Digital Pathology Research in Life Sciences. Lab Bulletin. June 20, 2024. Available at:
https://www.labbulletin.com/ articles/indica-labs-announces-aipowered-halo-software-release (accessed May 21, 2025).
31. Global Alzheimer’s Platform Foundation. Beckman Coulter Diagnostics Joins the Transformative Bio-Hermes-002 Study as New Partner. Global Alzheimer’s Platform Foundation. Press Release. January 23, 2025. Available at:
https://globalalzplatform.org/2025/01/23/beckman-coulter- diagnostics-joins-the-transformative-bio-hermes-002-study-as-new-partner/ (accessed May 21, 2025).
Read, Share and Comment on this Article, visit:
www.labmate-online.com/article
of companies, empowered by partnerships with top-tier research institutions, is driving the acceleration of this transformation. Our operating companies are at the forefront, leading the way from enabling discovery for the long-term to bringing diagnostics to the clinic and empowering development of disease-modifying therapies for AD patients.
AD, once an enigma of tangled proteins and cognitive shadows, is being unravelled at the molecular level. As the defi nition of AD evolves to include metabolic dysfunction and insulin-signalling impairment, our approaches to diagnosis and treatment are also shifting. The integration of omics technologies, AI, and collaborative innovation heralds a new era in neurology - one where precision medicine is not a distant dream, but an emerging standard. Through the contributions of researchers worldwide and their partners in industry, we are inching closer to a reality in which AD can be diagnosed early, treated effectively, and perhaps one day, prevented entirely.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
